255 related articles for article (PubMed ID: 19120973)
21. Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR.
Sun Y; Song M; Jäger E; Schwer C; Stevanovic S; Flindt S; Karbach J; Nguyen XD; Schadendorf D; Cichutek K
Clin Cancer Res; 2008 Jul; 14(13):4306-15. PubMed ID: 18594014
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
23. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
[TBL] [Abstract][Full Text] [Related]
24. Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells.
Hatakeyama N; Tamura Y; Sahara H; Suzuki N; Suzuki K; Hori T; Mizue N; Torigoe T; Tsutsumi H; Sato N
Exp Hematol; 2006 Feb; 34(2):197-207. PubMed ID: 16459188
[TBL] [Abstract][Full Text] [Related]
25. In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity.
Doubrovina ES; Doubrovin MM; Lee S; Shieh JH; Heller G; Pamer E; O'Reilly RJ
Clin Cancer Res; 2004 Nov; 10(21):7207-19. PubMed ID: 15534094
[TBL] [Abstract][Full Text] [Related]
26. Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.
Tamanaka T; Oka Y; Fujiki F; Tsuboi A; Katsuhara A; Nakajima H; Hosen N; Nishida S; Lin YH; Tachino S; Akatsuka Y; Kuzushima K; Oji Y; Kumanogoh A; Sugiyama H
Anticancer Res; 2012 Dec; 32(12):5201-9. PubMed ID: 23225417
[TBL] [Abstract][Full Text] [Related]
27. Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587.
Wen W; Zhang L; Peng J; Chen J; Hao J; Li X; Qian X; Zeng P; Zhang Y; Yin Y
Cancer Sci; 2011 Aug; 102(8):1455-61. PubMed ID: 21595801
[TBL] [Abstract][Full Text] [Related]
28. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer.
Azumi M; Kobayashi H; Aoki N; Sato K; Kimura S; Kakizaki H; Tateno M
J Urol; 2010 May; 183(5):2036-44. PubMed ID: 20303532
[TBL] [Abstract][Full Text] [Related]
29. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
[TBL] [Abstract][Full Text] [Related]
30. Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients.
Mizote Y; Taniguchi T; Tanaka K; Isobe M; Wada H; Saika T; Kita S; Koide Y; Uenaka A; Nakayama E
Vaccine; 2010 Jul; 28(32):5338-46. PubMed ID: 20665979
[TBL] [Abstract][Full Text] [Related]
31. P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells.
Chikamatsu K; Albers A; Stanson J; Kwok WW; Appella E; Whiteside TL; DeLeo AB
Cancer Res; 2003 Jul; 63(13):3675-81. PubMed ID: 12839958
[TBL] [Abstract][Full Text] [Related]
32. Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients.
Alisa A; Ives A; Pathan AA; Navarrete CV; Williams R; Bertoletti A; Behboudi S
Clin Cancer Res; 2005 Sep; 11(18):6686-94. PubMed ID: 16166448
[TBL] [Abstract][Full Text] [Related]
33. Defining MHC class II T helper epitopes for WT1 tumor antigen.
Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
[TBL] [Abstract][Full Text] [Related]
34. CD4+ T cells from type 1 diabetic and healthy subjects exhibit different thresholds of activation to a naturally processed proinsulin epitope.
Yang J; Danke N; Roti M; Huston L; Greenbaum C; Pihoker C; James E; Kwok WW
J Autoimmun; 2008 Aug; 31(1):30-41. PubMed ID: 18385016
[TBL] [Abstract][Full Text] [Related]
35. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
Jandus C; Bioley G; Dojcinovic D; Derré L; Baitsch L; Wieckowski S; Rufer N; Kwok WW; Tiercy JM; Luescher IF; Speiser DE; Romero P
Cancer Res; 2009 Oct; 69(20):8085-93. PubMed ID: 19808957
[TBL] [Abstract][Full Text] [Related]
36. CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope.
Campi G; Crosti M; Consogno G; Facchinetti V; Conti-Fine BM; Longhi R; Casorati G; Dellabona P; Protti MP
Cancer Res; 2003 Dec; 63(23):8481-6. PubMed ID: 14679013
[TBL] [Abstract][Full Text] [Related]
37. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes.
Makita M; Hiraki A; Azuma T; Tsuboi A; Oka Y; Sugiyama H; Fujita S; Tanimoto M; Harada M; Yasukawa M
Clin Cancer Res; 2002 Aug; 8(8):2626-31. PubMed ID: 12171894
[TBL] [Abstract][Full Text] [Related]
38. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
Sugiyama H
Expert Rev Vaccines; 2005 Aug; 4(4):503-12. PubMed ID: 16117707
[TBL] [Abstract][Full Text] [Related]
39. Recognition of CMV pp65 protein antigen by human CD4 T-cell lines induced with an immunodominant peptide pool.
Li Pira G; Bottone L; Ivaldi F; Pelizzoli R; Bracci L; Lozzi L; Scarso L; Tripodi G; Manca F
Hum Immunol; 2004 May; 65(5):537-43. PubMed ID: 15172454
[TBL] [Abstract][Full Text] [Related]
40. Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2.
Ayyoub M; Merlo A; Hesdorffer CS; Speiser D; Rimoldi D; Cerottini JC; Ritter G; Chen YT; Old LJ; Stevanovic S; Valmori D
Clin Immunol; 2005 Jan; 114(1):70-8. PubMed ID: 15596411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
